Primary biliary cholangitis: Epidemiology, prognosis, and treatment
J Trivella, BV John, C Levy - Hepatology communications, 2023 - journals.lww.com
Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease
characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the …
characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the …
[HTML][HTML] Hepatic fibrosis: concept to treatment
Understanding the molecular mechanisms underlying liver fibrogenesis is fundamentally
relevant to develo** new treatments that are independent of the underlying etiology. The …
relevant to develo** new treatments that are independent of the underlying etiology. The …
[PDF][PDF] Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases
KD Lindor, CL Bowlus, J Boyer, C Levy, M Mayo - Hepatology, 2019 - Wiley Online Library
This American Association for the Study of Liver Diseases (AASLD) 2018 Practice Guidance
on Primary Biliary Cholangitis (PBC) is an update of the PBC guidelines published in 2009 …
on Primary Biliary Cholangitis (PBC) is an update of the PBC guidelines published in 2009 …
EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis
Primary biliary cholangitis (PBC) is a chronic inflammatory autoimmune cholestatic liver
disease, which when untreated will culminate in end-stage biliary cirrhosis. Diagnosis is …
disease, which when untreated will culminate in end-stage biliary cirrhosis. Diagnosis is …
The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines
Primary biliary cholangitis (formerly known as primary biliary cirrhosis, PBC) is an
autoimmune liver disease in which a cycle of immune mediated biliary epithelial cell injury …
autoimmune liver disease in which a cycle of immune mediated biliary epithelial cell injury …
Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy
Background & Aims Approaches to risk stratification for patients with primary biliary cirrhosis
(PBC) are limited, single-center based, and often dichotomous. We aimed to develop and …
(PBC) are limited, single-center based, and often dichotomous. We aimed to develop and …
Evidence-based clinical practice guidelines for liver cirrhosis 2015
H Fukui, H Saito, Y Ueno, H Uto, K Obara… - Journal of …, 2016 - Springer
Abstract The Japanese Society of Gastroenterology revised the evidence-based clinical
practice guidelines for liver cirrhosis in 2015. Eighty-three clinical questions were selected …
practice guidelines for liver cirrhosis in 2015. Eighty-three clinical questions were selected …
Evolving therapies for liver fibrosis
Fibrosis is an intrinsic response to chronic injury, maintaining organ integrity when extensive
necrosis or apoptosis occurs. With protracted damage, fibrosis can progress toward …
necrosis or apoptosis occurs. With protracted damage, fibrosis can progress toward …
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association For The Study Of The Liver - Journal of hepatology, 2009 - Elsevier
EASL Clinical Practice Guidelines (CPG) on the management of cholestatic liver diseases
define the use of diagnostic, therapeutic and preventive modalities, including non-invasive …
define the use of diagnostic, therapeutic and preventive modalities, including non-invasive …
Hepatic inflammation and progressive liver fibrosis in chronic liver disease
AJ Czaja - World journal of gastroenterology: WJG, 2014 - pmc.ncbi.nlm.nih.gov
Chronic liver inflammation drives hepatic fibrosis, and current immunosuppressive, anti-
inflammatory, and anti-viral therapies can weaken this driver. Hepatic fibrosis is reversed …
inflammatory, and anti-viral therapies can weaken this driver. Hepatic fibrosis is reversed …